Clovis Oncology Inc.Find Ratings Reports
CLOVIS ONCOLOGY INC's gross profit margin for the fourth quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. The company has grown sales and net income significantly, outpacing the average growth rates of competitors within its industry. CLOVIS ONCOLOGY INC is extremely liquid. Currently, the Quick Ratio is 7.02 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 10,216.56% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY17||Q4 FY16|
|Net Sales ($mil)||17.04||0.08|
|Net Income ($mil)||-51.88||-70.73|
|Balance Sheet||Q4 FY17||Q4 FY16|
|Cash & Equiv. ($mil)||563.73||266.18|
|Total Assets ($mil)||735.23||364.56|
|Total Debt ($mil)||282.41||281.13|
|Profitability||Q4 FY17||Q4 FY16|
|Gross Profit Margin||81.75||-85017.95|
|Return on Assets||-47.11||-95.77|
|Return on Equity||-94.22||0.0|
|Debt||Q4 FY17||Q4 FY16|
|Share Data||Q4 FY17||Q4 FY16|
|Shares outstanding (mil)||50.57||38.72|
|Div / share||0.0||0.0|
|Book value / share||7.27||-0.09|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1311234.0||1195246.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 8.45 indicates a significant premium versus the S&P 500 average of 3.15 and a significant discount versus the industry average of 22.16. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, CLOVIS ONCOLOGY INC proves to trade at a discount to investment alternatives within the industry.
|CLVS NM||Peers 42.18||CLVS NM||Peers 28.08|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CLVS's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CLVS's P/CF is negative making the measure meaningless.
|CLVS NM||Peers 60.15||CLVS NA||Peers 0.38|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
CLVS's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CLVS 8.45||Peers 22.16||CLVS 17.43||Peers -3.51|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CLVS is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
CLVS is expected to have an earnings growth rate that significantly exceeds its peers.
|CLVS 55.97||Peers 58.17||CLVS 71067.94||Peers 586.99|
Average. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CLVS is trading at a valuation on par with its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
CLVS has a sales growth rate that significantly exceeds its peers.